Experimental drug NU-9 reduces toxic amyloid in early Alzheimer’s

2025-12-22T13:30:52

Amyloid,Targeted,Therapy,As,Plaques,Made,Of,Abnormal,Clusters,Of

A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member